GL1X · GenesisL1 explorer

Research workbench

Cryo-EM structure of PDR5 from saccharomyces cerevisiae in outward- facing conformation with ADP-ORTHOVANADATE/ATP

Analyse Cryo-EM structure of PDR5 from saccharomyces cerevisiae in outward- facing… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7P06
Type
protein
Length
1,350 residues
Chains
1
Method
electron microscopy
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Pleiotropic ABC efflux transporter of multiple drugs
UniProt
P33302
Ligands
ATP, AOV, MG
Pockets
17 · best druggability 0.86

Structure

electron microscopy · 1 distinct chain · 53% helix, 10% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
APleiotropic ABC efflux transporter of multiple drugsprotein135053% helix, 10% strandP33302

Ligands and binding sites

  • ATP · Adenosine-5'-triphosphate · ligand · chains A
  • AOV · Adp orthovanadate · ligand · chains A
  • MG · Magnesium ion · metal · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

17 pockets found on a 1 Å grid, 10 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
19190.860.88115ATP, MG, AOV
24390.810.8940empty
33220.780.8943empty
410400.780.7974empty
5900.760.9825empty

Modifications

Observed in the structure: 3 disulfide (disulfide).

Compared structures

  • 7P06 · Cryo-EM structure of Pdr5 from Saccharomyces cerevisiae in outward-facing conformation… · the same entry in another collection · chain A against A, TM-score 1.00
  • P33302 · AlphaFold monomer V2.0 prediction for pleiotropic ABC efflux transporter of multiple… · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.